<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01326364</url>
  </required_header>
  <id_info>
    <org_study_id>PANC0009</org_study_id>
    <secondary_id>SU-03182010-5282</secondary_id>
    <nct_id>NCT01326364</nct_id>
  </id_info>
  <brief_title>Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection</brief_title>
  <official_title>Prognostic Value of Baseline CT Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is first, to determine whether baseline perfusion characteristics
      of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to
      treatment by stereotactic body radiotherapy (SBRT). The second goal of this study is to
      determine whether baseline perfusion characteristics in those patients with resectable
      pancreatic cancer correlate with immunohistologic markers of angiogenesis such as microvessel
      density and vascular endothelial growth factor (VEGF) expression.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Histological markers of tumor angiogenesis (microvessel density, EGF/VEGF expression level)</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tumor response to treatment in SBRT patients, based on WHO criteria (No Change/Progressive Disease vs. Partial/Complete Response)</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Pancreatic Cancer</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stereotactic body radiotherapy</intervention_name>
    <description>Standard of Care</description>
    <other_name>CyberKnife</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iodixanol</intervention_name>
    <description>IV, calculated per patient</description>
    <other_name>Visipaque</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iohexol</intervention_name>
    <description>IV, Calculated per patient</description>
    <other_name>Omnipaque</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        pancreatic adenocarcinoma
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. suspected and/or biopsy-proven pancreatic adenocarcinoma, and

          2. referral to Radiology for pre-treatment baseline pancreatic protocol CT.

        Exclusion criteria:

        1) are absolute contraindications to intravenous iodinated contrast or CT scan.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aya Kamaya</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 14, 2010</study_first_submitted>
  <study_first_submitted_qc>March 29, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 30, 2011</study_first_posted>
  <last_update_submitted>June 30, 2016</last_update_submitted>
  <last_update_submitted_qc>June 30, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 1, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

